TVAX Biomedical Overview
- Year Founded
-
2004
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$500K
- Investors
-
2
TVAX Biomedical General Information
Description
Developer of cell-based immunotherapies designed to treat aggressive solid cancers. The company's technology utilizes a dual-mechanism approach combining personalized cancer cell vaccination with activated killer T-cell therapy, enabling healthcare providers to target glioblastoma and other solid tumors through autologous cell processing that overcomes immune suppression and reduces treatment toxicity.
Contact Information
Website
www.tvaxbiomedical.comCorporate Office
- PO Box 19311
- Lenexa, KS 66285-9311
- United States
Corporate Office
- PO Box 19311
- Lenexa, KS 66285-9311
- United States
TVAX Biomedical Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Later Stage VC | 27-Jun-2024 | $500K | Completed | Clinical Trials - Phase 2 | ||
| 10. Secondary Transaction - Private | Completed | Clinical Trials - Phase 2 | ||||
| 9. Grant | 18-Oct-2022 | Completed | Clinical Trials - Phase 2 | |||
| 8. Later Stage VC | 15-Mar-2016 | Completed | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC | 30-Mar-2015 | Completed | Clinical Trials - Phase 2 | |||
| 6. Later Stage VC | 15-Apr-2013 | Completed | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC | 12-Dec-2012 | Completed | Clinical Trials - Phase 2 | |||
| 4. IPO | 17-May-2012 | Cancelled | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC | 28-Apr-2011 | $5.67M | $7.67M | Completed | Clinical Trials - Phase 1 | |
| 2. Later Stage VC | 15-Dec-2010 | $1.6M | $2M | Completed | Clinical Trials - Phase 1 |
TVAX Biomedical Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
TVAX Biomedical Comparisons
Industry
Financing
Details
TVAX Biomedical Competitors (56)
One of TVAX Biomedical’s 56 competitors is Centrose, a Venture Capital-Backed company based in Madison, WI.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Aura Biosciences | Formerly VC-backed | Boston, MA | ||||
| Allorion Therapeutics | Venture Capital-Backed | Natick, MA | ||||
| Iovance Biotherapeutics | Corporation | San Carlos, CA |
TVAX Biomedical Patents
TVAX Biomedical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2010104836-A1 | Infectious disease cellular immunotherapy | Inactive | 09-Mar-2009 | ||
| DE-60032622-D1 | Composition and method for cancer antigen immunotherapy | Inactive | 05-Oct-1999 | ||
| DE-60032622-T2 | Composition and method for cancer antigen immunotherapy | Inactive | 05-Oct-1999 | ||
| ES-2279772-T3 | Composition and method of antigenic antigenic immunotherapy. | Inactive | 05-Oct-1999 | ||
| EP-1225870-A1 | Composition and method of cancer antigen immunotherapy | Active | 05-Oct-1999 | A61K40/11 |
TVAX Biomedical Signals
TVAX Biomedical Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| eGrowth Ventures | Not-For-Profit Venture Capital | Minority | ||
| FDA Orphan | Other |
TVAX Biomedical Investments (1)
TVAX Biomedical’s most recent deal was a Joint Venture with V2ACT Therapeutics. The deal was made on 01-Jan-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| V2ACT Therapeutics | 01-Jan-2019 | Joint Venture | Drug Discovery |
TVAX Biomedical FAQs
-
When was TVAX Biomedical founded?
TVAX Biomedical was founded in 2004.
-
Where is TVAX Biomedical headquartered?
TVAX Biomedical is headquartered in Lenexa, KS.
-
What is the size of TVAX Biomedical?
TVAX Biomedical has 4 total employees.
-
What industry is TVAX Biomedical in?
TVAX Biomedical’s primary industry is Biotechnology.
-
Is TVAX Biomedical a private or public company?
TVAX Biomedical is a Private company.
-
What is TVAX Biomedical’s current revenue?
The current revenue for TVAX Biomedical is .
-
How much funding has TVAX Biomedical raised over time?
TVAX Biomedical has raised $14.6M.
-
Who are TVAX Biomedical’s investors?
eGrowth Ventures and FDA Orphan have invested in TVAX Biomedical.
-
Who are TVAX Biomedical’s competitors?
Centrose, Inovio Pharmaceuticals, Aura Biosciences, Allorion Therapeutics, and Iovance Biotherapeutics are some of the 56 competitors of TVAX Biomedical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process